Arthritis Associates — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$633	1
2023	Research	$6,022	3
2022	Research	$33,250	2
2021	Research	$11,867	2
2020	Research	$47,885	13
2019	Research	$16,200	4

Breakdown

Who paid Research payments · program years 2019–2024

E.R. Squibb & Sons, L.L.C. $76,874 7 payments
GlaxoSmithKline, LLC. $37,400 15 payments
Seattle Genetics, Inc. $1,000 1 payment
AbbVie, Inc. $584 2 payments

Studies the money was for Research payments · program years 2019–2024

Phase III PsA #2 - A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis (PsA) who are Naive to Biologic Disease Modifying Anti-rhe $38,688 3 payments
A 5-Year Prospective Observational Registry to Assess Adverse Events O $37,400 15 payments
A Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Multiple Doses of BMS-986165 in Subjects With Active Psoriatic Arthritis (PsA) $28,052 2 payments
Phase III PsA #2 $9,500 1 payment
A Multi-center, Randomized, Double-blinded, Placebo-controlled, Multiple-ascending-dose Study of Brentuximab Vedotin in Adults With Active Systemic Lupus Erythematosus $1,000 1 payment
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment $633 1 payment
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function. This study evaluates how safe and effective ABBV-154 is in participants treated for moderately to severely active RA. Adverse events and change in the disease activity will be assessed. $333 1 payment
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) $251 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.